Beqvez access in UAE: the EDE named-patient pathway
How UAE patients legally obtain Beqvez (fidanacogene elaparvovec-dzkt) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Important: Pfizer stopped developing and selling Beqvez worldwide in February 2025, so new supply is not available. If Beqvez was suggested, ask your haematologist about other options for haemophilia B, such as the gene therapy Hemgenix or factor IX prophylaxis. You can ask us about access to an FDA-approved alternative.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Ask about Beqvez in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Beqvez (fidanacogene elaparvovec-dzkt) is AAV-Rh74var-based gene therapy delivering a high-activity variant of factor IX (Padua variant) approved by the US FDA in April 2024 for haemophilia B in adults with moderately severe to severe disease who currently use factor IX prophylaxis, have current or historical life-threatening haemorrhage, or have repeated serious spontaneous bleeding episodes; patients must be antibody negative to the AAV-Rh74var variant capsid. The drug is manufactured by Pfizer. UAE patients use the Emirates Drug Establishment named-patient pathway when the locally registered indication, the stocked presentation, or the available payer coverage does not match what the prescribing physician has written. Reserve Meds coordinates supply through a US-licensed pharmaceutical wholesale partner, builds the documentation packet your physician needs to file, and orchestrates the logistics into UAE with a single point of contact carrying the case end-to-end.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Beqvez reaches patients in the UAE
Beqvez (fidanacogene elaparvovec-dzkt, an AAVRh74var-based gene therapy from Pfizer carrying a high-activity factor IX Padua variant, FDA-approved 25 April 2024 for adults with moderate to severe haemophilia B who use factor IX prophylaxis, have current or historical life-threatening haemorrhage, or have repeated serious spontaneous bleeding episodes, and who do not have neutralising antibodies to AAVRh74var) is not currently visible on UAE federal drug-registration listings as of 2026-06-01. Personal-use access is administered under the Permit to Import Medicines for Personal Use, which was transferred from the Ministry of Health and Prevention (MOHAP) to the Emirates Drug Establishment (EDE) effective 29 December 2025 per the MOHAP announcement at mohap.gov.ae/en/mte. New personal-import applications route through the EDE portal at ede.gov.ae; the EDE service infographic is available at ede.gov.ae personal-use infographic. The legal basis is Federal Law No. 8 of 2019 on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments, and the Cabinet Decision implementing regulations. Facility licensing and clinical practice remain at the emirate authority level (Department of Health Abu Dhabi at doh.gov.ae and Dubai Health Authority at dha.gov.ae). For Beqvez specifically, the EDE file must reference confirmed moderate to severe haemophilia B with documented factor IX activity below 2 IU per dL, prior factor IX prophylaxis history, a negative AAVRh74var neutralising antibody titre confirmed via the Pfizer-recommended assay at a qualified reference laboratory, baseline liver function with absence of significant fibrosis on imaging, the planned single-infusion administration date at an authorised UAE haemophilia treatment centre, and the 52-week corticosteroid-tapered post-infusion monitoring plan per the BENEGENE-2 phase 3 trial (NCT03861273). The prescribing haematologist must be DoH or DHA licensed.
Where Beqvez is dispensed in the UAE
Beqvez is a one-time intravenous AAV gene therapy infusion administered in an adult haemophilia treatment centre with capability for the post-infusion corticosteroid-tapered monitoring of transaminases, factor IX activity, and AAV-vector-related immune response. The receiving centre must be DoH Abu Dhabi or DHA Dubai licensed for adult haematology and gene therapy and must agree to participate in long-term post-marketing follow-up per the FDA-required commitments. Sidra Medicine in Doha is paediatric only and does not apply to this adult-only Beqvez profile; UAE paediatric haematology is provided at Al Jalila Children's Specialty Hospital in Dubai at aljalilachildrens.ae but this is outside the FDA-approved Beqvez age range.
What Beqvez costs in the UAE
Medicine price: quote on request. You get a written quote for your case before you commit. Cost layers above the drug cost include validated cryogenic logistics of the gene-therapy vial from the Pfizer manufacturer to the UAE haemophilia treatment centre under continuous monitoring, baseline AAVRh74var neutralising antibody assay at the qualified reference laboratory, baseline and longitudinal liver imaging (FibroScan, MRI elastography), the day-of-infusion inpatient infusion bay fee, a 52-week corticosteroid-tapered monitoring schedule with frequent transaminase and factor IX activity testing, and the Reserve Meds coordination fee itemised separately on every firm quote. Pfizer US patient assistance programmes do not extend to UAE residents.
Funding and access barriers for Beqvez in the UAE
UAE haemophilia care for citizens is funded through emirate-level structures. Abu Dhabi citizens (Thiqa) receive full-spectrum coverage administered by Daman National Health Insurance at daman.ae covering specialty haematology and gene-therapy procedures at SEHA facilities with prior authorisation. Lower-income Abu Dhabi residents (Daman Basic) and the Department of Health Abu Dhabi reimbursement channel through Daman cover named-patient imports case-by-case. Dubai's mandatory health insurance scheme (Essential Benefits Plan for private-sector residents, Salama or ENAYA for UAE nationals working in Dubai government) is policy-specific for specialty gene therapy. MOHAP-administered care for UAE nationals at federal Northern Emirates facilities (Sharjah, Ajman, Ras Al Khaimah, Fujairah, Umm Al Quwain) is largely out-of-pocket free for specialty care for nationals. Medicine price: quote on request. You get a written quote for your case before you commit. Major private insurers including Daman, Bupa Arabia, AXA Gulf, MetLife, Oman Insurance Company (Sukoon), Cigna Middle East, Allianz Worldwide Care, Mednet, Nextcare, and NAS apply prior-authorisation gating to specialty gene therapy with sub-limits. The structural access constraint specific to Beqvez is the AAVRh74var neutralising antibody screen (approximately 40 to 60 percent of adults have pre-existing neutralising antibodies against the vector and are ineligible per the FDA label).
Recent regulatory and access news for Beqvez
MOHAP announced on 29 December 2025 the transfer of the personal-use import permit service (and selected other services) to the Emirates Drug Establishment, with new applications routed through ede.gov.ae at mohap.gov.ae/en/mte. Federal Law No. 8 of 2019 implementing regulations continue to be supplemented by Cabinet Decisions on pricing, pharmacovigilance, and import-pathway specifics. On the manufacturer side, Pfizer announced in February 2025 it would discontinue commercial promotion of Beqvez globally citing low uptake at launch (under 10 patients dosed worldwide in the first nine months despite the FDA approval), and Pfizer publicly indicated it would continue to honour patient-by-patient infusion requests through the established gene-therapy distribution channel. This is a material development for any UAE Beqvez personal-import file and the prescribing haematologist must confirm with the Pfizer haemophilia gene-therapy team that the patient's single-infusion procedure can be supported under the residual programme. No EDE or MOHAP bulletin for Beqvez over the last 12 months has been observed as of 2026-06-01.
Where Reserve Meds fits in Beqvez cases
Reserve Meds is a US-based digital health company. We do not replace your UAE specialist, we do not replace the EDE, and we do not replace your dispensing pharmacy. For Beqvez specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate logistics into UAE, and give you one point of contact through the case. The pharmacist-of-record review, prescription validation, biomarker confirmation, and physician sign-off are the recurring operational fundamentals for this drug.
Next step
If your UAE physician has prescribed Beqvez and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.